Accessibility Menu
Sana Biotechnology logo

Sana Biotechnology(NASDAQ) SANA

Current Price$3.12
Market Cap$893.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-91%
5 Year-83%
1 Year-38%
1 Month-4%
Sana Biotechnology last closing stock price
MetricPriceDate
Last closeUSD 3.212026-07-23
Sana Biotechnology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.26%USD 3.172026-07-16
1 month-4.18%USD 3.352026-06-23
3 month-2.43%USD 3.292026-04-24
Year to date-21.13%USD 4.072025-12-31
1 year-37.55%USD 5.142025-07-23
3 year-46.32%USD 5.982023-07-24
5 year-82.7%USD 18.562021-07-23
Since inception-91.11%USD 35.102021-02-04

Sana Biotechnology Financials at a Glance

Market Cap

$893.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$241.99M

EPS (TTM)

-$0.94

P/E Ratio

-3.42

Dividend

$0.00

Beta (Volatility)

2.13 (High)

Price

$3.12

Volume

12,896

Open

$3.20

Previous Close

$3.21

Daily Range

$3.12 - $3.27

52-Week Range

$2.61 - $6.55

Estimated Earnings Date

Aug 10, 2026

SANA News

smart-investor-studying-stock-charts-getty

2 Growth Stocks That Jumped 42% and 58% Last Week: Can They Still Climb Higher?

Cory RenauerApr 17, 2023
scientists examine cell make up microscope biotech

Why Shares of Sana Biotechnology Jumped This Week

James HalleyApr 14, 2023
IPO and stock chart

2 Biotech IPO Stocks You'll Want to Have on Your Radar

Keith SpeightsJul 11, 2021

SANA: Motley Fool Moneyball Superscore

52

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sana Biotechnology

Sana makes new medicines from engineered human cells. These treatments help people with diabetes and cancer. The company works to repair or replace sick cells.

The Product Pipeline

  • SC451: Stem cell-derived treatment for Type 1 diabetes; uses technology to hide cells from the patient's immune system.
  • SG293: Genetic therapy delivered inside the body; targets T cells to treat cancers and autoimmune diseases.
  • UP421: Primary cell therapy; used in human studies to prove cells can survive without immune-suppressing drugs.
  • Hypoimmune Platform: Genetic editing system; modifies cells so they are not rejected by the body after transplantation.
  • Fusogen Platform: Delivery technology; sends genetic instructions to specific cells without removing them from the patient.

Growth and Focused Strategy

  • Suspended development of allogeneic CAR T programs in November 2025 to prioritize diabetes and in vivo programs.
  • Completed the first-in-human transplant of UP421 in December 2024 at Uppsala University Hospital.
  • Advanced the SG293 program following preclinical studies in January 2026 that showed successful B cell depletion.

What Makes Sana Stand Out

The company specializes in creating cells that can survive in a patient's body without the need for lifelong immune-suppressing drugs. Its delivery technology aims to turn a patient's own cells into medicine, avoiding the high cost and complexity of lab-based manufacturing.

By the Numbers

  • Net loss deepened to $58.8 million in Q4 2025, worsening 19.9% from $49.1 million in Q4 2024.
  • Operating loss was $61.2 million in Q4 2025, worsening 20.3% from $50.9 million in the previous year.
  • Market capitalization reached $1 billion in Q4 2025, up 167.6% from $385.2 million in Q4 2024.
  • Free cash flow was negative $33.5 million in Q4 2025, improving 29.6% from negative $47.6 million in Q4 2024.

The Long View

Sana has transitioned from broad research to a focused clinical stage developer specializing in diabetes and genetic delivery. Its survival depends on proving that engineered cells can function permanently in the body while evading immune detection.

AI Generated • May 3, 2026

Industry

Biotechnology

Sector

Health Care

Employees

142

CEO

Steven D. Harr, MD

Website

www.sana.com

Headquarters

Seattle, WA 98102, US

SANA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-161.87%

Return on Capital

-79.65%

Return on Assets

-64.77%

Earnings Yield

-29.24%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$893.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

278.29M

Volume

12.90K

Avg. Volume

3.67M

Financials (TTM)

Gross Profit

-$2.39M

Operating Income

-$237.56M

EBITDA

-$187.06M

Operating Cash Flow

-$132.55M

Capital Expenditure

-$1.09M

Free Cash Flow

-$133.64M

Cash & ST Invst.

$101.14M

Total Debt

$75.33M

Sana Biotechnology Performance Analysis

Sana Biotechnology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Sana Biotechnology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Sana Biotechnology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.43-33.1%
20232023-12-31USD -1.461.8%
20242024-12-31USD -1.16-20.6%
20252025-12-31USD -0.96-16.5%
Sana Biotechnology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-85.7%
Q32025-09-3059.0%
Q42025-12-31-25.0%
Q12026-03-3115.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$2.39M

N/A

Gross Margin

0.00%

N/A

Market Cap

$893.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.29M

N/A

Employees

142

N/A

Net Income

-$47.21M

+4.4%

EBITDA

-$44.82M

+2.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$101.14M

-3.4%

Total Debt

$75.33M

-17.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$60.45M

-22.8%

Short Term Debt

$14.88M

+14.4%

Return on Assets

-64.77%

N/A

Return on Invested Capital

-82.68%

N/A

Free Cash Flow

-$37.67M

+22.8%

Operating Cash Flow

-$37.38M

+23.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PHATPhathom Pharmaceuticals, Inc.
$11.41-1.65%
OCSOculis Holding AG
$11.05-3.40%
INBXInhibrx Biosciences Inc.
$82.36-3.11%
NKTRNektar Therapeutics
$71.16+2.59%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.37-0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$64.38-0.03%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$44.53+0.03%
TSLATesla
$311.61-0.03%

Questions About SANA

What is the current price of Sana Biotechnology?

Sana Biotechnology is trading at $3.12 per share.

What is the 52-week range for Sana Biotechnology?

Over the past 52 weeks, Sana Biotechnology has traded between $2.61 and $6.55.

How much debt does Sana Biotechnology have?

As of the most recent reporting period, Sana Biotechnology reported total debt of $75.33M.

How much cash does Sana Biotechnology have on hand?

Sana Biotechnology reported $88.00M in cash and cash equivalents in its most recent financial results.

What is Sana Biotechnology’s dividend yield?

Sana Biotechnology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services